Brief: Advaxis ADXS-503 (HOT Lung) Demonstrates Pronounced And Sustained Tumor Control In Ongoing Phase 1/2 Lung Cancer Trial

Ayala Pharmaceuticals

26/10/2020 12:27

Oct 26 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS’ ADXS-503 (HOT LUNG) DEMONSTRATES PRONOUNCED AND
SUSTAINED TUMOR CONTROL IN ONGOING PHASE 1/2 LUNG CANCER TRIAL
    * ADVAXIS INC - APPROXIMATE 50% IMPROVEMENT IN DISEASE
CONTROL
RATE VERSUS RATES REPORTED IN OTHER CHECKPOINT RECHALLENGE
STUDIES
    * ADVAXIS INC - DISEASE CONTROL RATE OF 67% IN FIRST SIX
EVALUABLE
PATIENTS WHO HAD PROGRESSED ON KEYTRUDA
    * ADVAXIS INC - DURABLE, SUSTAINED TUMOR CONTROL OF OVER 43
AND33
WEEKS OBSERVED IN FIRST TWO EVALUABLE PATIENTS

Source text for Eikon:  ID:nGNX5RzMqN 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))